Defence Therapeutics (TSE:DTC)
:DTC
Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.46 - C$0.95
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$28.68M
Enterprise ValueC$27.50M
Total Cash (Recent Filing)C$947.35K
Total Debt (Recent Filing)C$1.49M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding57,369,970
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe Accum® platform targets enhanced intracellular delivery and potency of biologics, a durable technical differentiator. If validated, it can raise clinical efficacy, support higher-value indications, and underpin licensing or partner deals that sustain long-term R&D returns.
Therapeutic Focus & ExpertiseA dual focus on oncology and infectious diseases plus ADC-related approaches increases addressable markets and strategic partnering options. This breadth supports durable relevance across high-growth therapeutic areas and diversification of clinical risk over multi-year development timelines.
Improving Cash MetricsReported improvements in annual net loss and positive TTM free cash flow growth signal initial cost control and operational discipline. If sustained, these trends extend runway, reduce near-term financing needs, and improve probability of advancing clinical programs to value-inflection points.
Bears Say
No Revenue / PrecommercialThe company has no commercial revenue, meaning value depends entirely on preclinical/clinical progress, milestone payments or future approvals. This structural lack of sales prolongs reliance on capital markets and magnifies execution risk over the medium term.
Negative Shareholders' EquityNegative equity reflects accumulated losses and likely dilution, reducing financial flexibility and complicating leverage assessment. This structural balance-sheet weakness limits options for non-dilutive financing and increases the probability of future equity issuance when funding is needed.
Sustained Cash BurnPersistent, material negative operating cash flow (~-4.9M TTM) indicates ongoing cash burn and funding dependence. Over 2–6 months this elevates the risk of program delays, prioritization cuts, or dilutive financings if revenue or partner funding does not materialize.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.46 and its highest was C$0.95 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$28.68M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 2 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -C$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.028.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.154%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---